Basic Information
| RNALocate ID: | RLID:11001479 |
| RNA Symbol: | hsa-miR-205-5p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-205 |
| RNA ID: | miRBase:MIMAT0000266 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 21601258 |
| Tissue/Cell Line: | Ascites fluid|Pleural effusion |
| Method: | qRT-PCR |
|
Originally published in Gynecol Oncol. Rupp AK, et al, 2011. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
| Description: | Biochemical marker analysis of exosomes. (A) Exosomes isolated from ascites or pleural effusions of tumor or LC patients were analyzed using the indicated mAb followed by peroxidase-conjugated secondary antibody and ECL detection. 10 μg exosomes were applied per lane. Note that HSP70, ADAM10, Annexin-1 and CD9 are considered as general exosome markers. HLA-DR was used as a marker for immune cell derived exosomes. Note that in BrCa patients #9-14 samples were derived from pleural effusions and #15 and 16 were from ascites. (B) The content of the indicated miRNAs was quantified by real-time RT-PCR in exosomes from ascites of OvCa (n=10) or LC patients (n=6) or BrCa pleural effusions (n=7). Note, that low Ct values reflect high expression levels of the respective miRNA. P-values in the figure are indicated as follows: * < 0.05, ** < 0.01 *** < 0.001. Data are collected from Figure 2. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001645 | Cytoplasm | Tumor tissues (Head|Neck) | 25422181 |
| RLID:01001646 | Nucleus | Tumor tissues (Head|Neck) | 25422181 |
| RLID:11001475 | Exosome | Urine | 26576778 |
| RLID:11001476 | Exosome | Primary ovarian tumor cells|Serum | 18589210 |
| RLID:11001477 | Exosome | Plasma | 19289371 |
| RLID:11001478 | Exosome | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) | 20615901 |
| RLID:11001480 | Exosome | Breast milk | 22211110 |
| RLID:11001481 | Exosome | Brain tissue | 23382797 |
| RLID:11001482 | Exosome | Plasma | 23663360 |
| RLID:11001483 | Microvesicle | Hepatocellular carcinoma cell line (HepG2)|Lung epithelial carcinoma cell line (A549) | 20615901 |
| RLID:11001484 | Microvesicle | Seminal plasma | 23539611 |
| RLID-D:11000057 | Exosome | Breast milk|Tongue tissue | |
| RLID-D:11000327 | Microvesicle | Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-205-5p | Splenic marginal zone lymphoma | MNDR-E-MI-27139 |
| MNDR | hsa-miR-205-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-27140 |
| MNDR | hsa-miR-205-5p | Uterine corpus endometrial carcinoma | MNDR-E-MI-27141 |
| MNDR | hsa-miR-205-5p | Lymphoma | MNDR-E-MI-27142 |
| MNDR | hsa-miR-205-5p | Lymphoma non-hodgkin | MNDR-E-MI-27143 |
| MNDR | hsa-miR-205-5p | Cutaneous t cell lymphoma | MNDR-E-MI-27144 |
| MNDR | hsa-miR-205-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-27145 |
| MNDR | hsa-miR-205-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-27146 |
| MNDR | hsa-miR-205-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-27147 |
| MNDR | hsa-miR-205-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-27148 |
| MNDR | hsa-miR-205-5p | Her2-receptor positive breast cancer | MNDR-E-MI-27149 |
| MNDR | hsa-miR-205-5p | Triple negative breast cancer | MNDR-E-MI-27150 |
| MNDR | hsa-miR-205-5p | Prostate cancer | MNDR-E-MI-27151 |
| MNDR | hsa-miR-205-5p | Prostate carcinoma | MNDR-E-MI-27152 |
| MNDR | hsa-miR-205-5p | Gastric cancer | MNDR-E-MI-27153 |
| MNDR | hsa-miR-205-5p | Gastric lymphoma | MNDR-E-MI-27154 |
| MNDR | hsa-miR-205-5p | Alzheimer disease | MNDR-E-MI-27155 |
| MNDR | hsa-miR-205-5p | Bladder cancer | MNDR-E-MI-27156 |
| MNDR | hsa-miR-205-5p | Esophageal carcinoma | MNDR-E-MI-27157 |
| MNDR | hsa-miR-205-5p | Head and neck cancer | MNDR-E-MI-27158 |
| MNDR | hsa-miR-205-5p | Hereditary hemorrhagic telangiectasia | MNDR-E-MI-27159 |
| MNDR | hsa-miR-205-5p | Ataxia telangiectasia | MNDR-E-MI-27160 |
| MNDR | hsa-miR-205-5p | Huntington disease | MNDR-E-MI-27161 |
| MNDR | hsa-miR-205-5p | Cardiovascular disease | MNDR-E-MI-27162 |
| MNDR | hsa-miR-205-5p | Lung cancer | MNDR-E-MI-27163 |
| MNDR | hsa-miR-205-5p | Endometrial cancer | MNDR-E-MI-27164 |
| MNDR | hsa-miR-205-5p | Parkinson disease | MNDR-E-MI-27165 |
| MNDR | hsa-miR-205-5p | Machado-joseph disease | MNDR-E-MI-27166 |
| MNDR | hsa-miR-205-5p | Breast cancer | MNDR-E-MI-27167 |
| MNDR | hsa-miR-205-5p | Aggressive squamous cell carcinoma | MNDR-E-MI-27168 |
| MNDR | hsa-miR-205-5p | Thyroid cancer | MNDR-E-MI-27169 |
| MNDR | hsa-miR-205-5p | Pituitary neoplasms | MNDR-E-MI-27170 |
| MNDR | hsa-miR-205-5p | Malignant mesothelioma | MNDR-E-MI-27171 |
| MNDR | hsa-miR-205-5p | Pancreatic cancer | MNDR-E-MI-27172 |
| MNDR | hsa-miR-205-5p | Melanoma | MNDR-E-MI-27173 |
| MNDR | hsa-miR-205-5p | Colon cancer | MNDR-E-MI-27174 |
| MNDR | hsa-miR-205-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-27175 |
| MNDR | hsa-miR-205-5p | Ovarian cancer | MNDR-E-MI-27176 |
| MNDR | hsa-miR-205-5p | Prostate adenocarcinoma | MNDR-E-MI-27177 |
| MNDR | hsa-miR-205-5p | Renal cancer | MNDR-E-MI-27178 |
| MNDR | hsa-miR-205-5p | Endometrial carcinoma | MNDR-E-MI-27179 |
| MNDR | hsa-miR-205-5p | Carcinoma ductal breast | MNDR-E-MI-27180 |
| MNDR | hsa-miR-205-5p | Balkan nephropathy | MNDR-E-MI-27181 |
| MNDR | hsa-miR-205-5p | Glioblastoma | MNDR-E-MI-27182 |
| MNDR | hsa-miR-205-5p | Glioma | MNDR-E-MI-27183 |
| MNDR | hsa-miR-205-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-27184 |
| MNDR | hsa-miR-205-5p | Osteosarcoma | MNDR-E-MI-27185 |
| MNDR | hsa-miR-205-5p | Breast carcinoma | MNDR-E-MI-27186 |
| MNDR | hsa-miR-205-5p | Uterine cancer | MNDR-E-MI-27187 |
| MNDR | hsa-miR-205-5p | Cervical adenocarcinoma | MNDR-E-MI-27188 |
| MNDR | hsa-miR-205-5p | Gastric adenocarcinoma | MNDR-E-MI-27189 |
| MNDR | hsa-miR-205-5p | Cervical squamous cell carcinoma | MNDR-E-MI-27190 |
| MNDR | hsa-miR-205-5p | Pituitary adenoma | MNDR-E-MI-27191 |
| MNDR | hsa-miR-205-5p | Lung squamous cell carcinoma | MNDR-E-MI-27192 |
| MNDR | hsa-miR-205-5p | Carcinoma lung non-small-cell | MNDR-E-MI-27193 |
| MNDR | hsa-miR-205-5p | Lung adenocarcinoma | MNDR-E-MI-27194 |
| MNDR | hsa-miR-205-5p | Thyroid carcinoma | MNDR-E-MI-27195 |
| MNDR | hsa-miR-205-5p | Ovarian carcinoma | MNDR-E-MI-27196 |
| MNDR | hsa-miR-205-5p | Bladder urothelial carcinoma | MNDR-E-MI-27197 |
| MNDR | hsa-miR-205-5p | Pancreatic adenocarcinoma | MNDR-E-MI-27198 |
| MNDR | hsa-miR-205-5p | Cervical cancer | MNDR-E-MI-27199 |
| MNDR | hsa-miR-205-5p | Biliary tract cancer | MNDR-E-MI-27200 |
| MNDR | hsa-miR-205-5p | Esophageal cancer | MNDR-E-MI-27201 |
| MNDR | hsa-miR-205-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-27202 |
| MNDR | hsa-miR-205-5p | Breast invasive carcinoma | MNDR-E-MI-27203 |
| MNDR | hsa-miR-205-5p | Hepatocellular carcinoma | MNDR-E-MI-27204 |
| MNDR | hsa-miR-205-5p | B-cell lymphoma | MNDR-E-MI-27205 |
| MNDR | hsa-miR-205-5p | Rheumatoid arthritis | MNDR-E-MI-27206 |
| MNDR | hsa-miR-205-5p | T-cell leukemia | MNDR-E-MI-27207 |
| MNDR | hsa-miR-205-5p | Neuroblastoma | MNDR-E-MI-27208 |
| MNDR | hsa-miR-205-5p | Barrett's adenocarcinoma | MNDR-E-MI-27209 |
| MNDR | hsa-miR-205-5p | Influenza | MNDR-E-MI-27210 |
| MNDR | hsa-miR-205-5p | Burkitt lymphoma | MNDR-E-MI-27211 |
| MNDR | hsa-miR-205-5p | Kb oral cancer | MNDR-E-MI-27212 |
| MNDR | hsa-miR-205-5p | Skin cutaneous melanoma | MNDR-E-MI-27213 |
| MNDR | hsa-miR-205-5p | Skin melanoma | MNDR-E-MI-27214 |
| MNDR | hsa-miR-205-5p | Colorectal cancer | MNDR-E-MI-27215 |
| MNDR | hsa-miR-205-5p | Nasopharyngeal carcinoma | MNDR-E-MI-27216 |
| MNDR | hsa-miR-205-5p | Nasopharynx carcinoma | MNDR-E-MI-27217 |
| MNDR | hsa-miR-205-5p | Multiple myeloma | MNDR-E-MI-27218 |
| MNDR | hsa-miR-205-5p | Ovarian epithelial cancer | MNDR-E-MI-27219 |
| MNDR | hsa-miR-205-5p | Esophageal squamous cell carcinoma | MNDR-E-MI-27220 |
| MNDR | hsa-miR-205-5p | Uterine cervical neoplasms | MNDR-E-MI-27221 |
| MNDR | hsa-miR-205-5p | Nasopharyngeal cancer | MNDR-E-MI-27222 |
| MNDR | hsa-miR-205-5p | Cerebral hemorrhage traumatic | MNDR-E-MI-27223 |
| MNDR | hsa-miR-205-5p | Intracranial hemorrhage hypertensive | MNDR-E-MI-27224 |
| MNDR | hsa-miR-205-5p | Barrett's carcinogenesis | MNDR-E-MI-27225 |
| MNDR | hsa-miR-205-5p | Breast cancer her3+ negative | MNDR-E-MI-27226 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ABCC2 | Homo sapiens | RR00023539 |
TOP